Drug Approval | October 29, 2025
FDA approves Alembic's Ticagrelor Tablets, 60 mg
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
Subscribe To Our Newsletter & Stay Updated
